p14^(ARF)、ARF-BP1及c-myc mRNA在肝细胞癌中的表达及临床意义

Expression of p14^(ARF),ARF-BP1 and c-myc mRNAs in hepatocellular carcinoma and their significances

目的:探讨肝细胞癌组织中p14ARF、ARF-BP1及c-myc的mRNA表达及其与临床参数关系.方法:采用半定量逆转录-聚合酶链式反应(RT-PCR)技术,对52例HCC组织及其中45例相应癌旁组织p14ARF、ARF-BP1及c-myc的mRNA表达丰度进行检测并分析他们之间的关系及其与临床参数的关系.结果:在52例HCC组织中p14ARF、ARF-BP1及c-myc的mRNA各表达77.0%、77.0%和75.0%,与45例相应癌旁组织(11.1%、20.0%、53.3%)比较,呈高表达.p14ARF、ARF-BP1mRNA的表达与肿瘤大小有关(t=2.169,2.087,均P<0.05);而c-mycmRNA表达与肿瘤大小无关.p14ARF、ARF-BP1及c-myc的mRNA表达在性别、年龄、AFP、临床病理分级、浸润转移、HBV、包膜等无统计学差异.p14ARF与ARF-BP1、p14ARF与c-myc及ARF-BP1与c-myc的mRNA表达两两成正相关(r=0.565,0.436,0.584,均P<0.01).结论:p14ARF、ARF-BP1、c-myc过度表达可能是HCC发生的早期指标;ARF-BP1过度表达可能是影响HCC发生、发展的关键,干预ARF-BP1可能是治疗HCC的新途径.

AIM： To investigate the expression of p14^ARF, ARF-BP1 and c-myc mRNAs in hepatocellular carcinoma （HCC） and their clinical significances. METHODS： Abundance of p14^ARF, ARF-BP1 and c-myc mRNAs was detected by semi-quantification reverse transcription polymerase chain reaction （RT-PCR） technique in the samples from 52 HCCs and their 45 non-tumorous liver tissues, and their clinical significances were assayed with the clinical parameters. RESULTS： The expression levels of p14^ARF, ARF-BP1 and c-myc mRNAs （77.0%, 77.0%, 75.0%） were higher in HCC tissues than those in the non-tumorous liver tissues （11.1%, 20.0%, 53.3%）, respectively. The expression of p14^ARF mRNA and ARF-BP1 mRNAs were related to tumor size （t = 2.169, 2.087; both P 〈 0.05）, but the expression of c-myc mRNA was not. The expression of p14^ARF, ARF-BP1 and c-myc mRNAs were not related to the gender, age, AFP level, clinical stageing, HBV infection, envelopes, infiltration and metastasis. There was a positive correlation between p14^ARF and ARF-BP1 expression, p14^ARF and c-myc expression as well as ARF-BP1 and c-myc expression （r = 0.565, 0.436, 0.584; all P 〈 0.01）. CONCLUSION： Over-expression of p14^ARF, ARF- BP1 and c-myc mRNAs are markers in the early stage of HCC, and ARF-BP1 over-expression play an important role in the genesis and development of HCC, ARF-BP1 may become a novel therapeutic target against HCC.